Sign in
CompletedPhase 3

A Study to Evaluate the Safety and Immunogenicity of RSVpreF Coadministered With Herpes Zoster Vaccine in Adults

Key facts

Who runs it
Pfizer
Where
Birmingham, Chesterfield, Chicago, Columbus, Doral, Fort Lauderdale, Houston, Huntsville, Los Angeles, Memphis, Mesquite, Miami, Mobile, New Orleans, New York, Peoria, Philadelphia, San Antonio, Silver Spring, Stockbridge, Sugar Land, Troy, Walnut Creek, and Warren Township, United StatesSee the 25 sitesAlso in 1 other country, 1 site
Trial code
Status
Completed
Phase
Phase 3
People taking part
526 people enrolled
Started
4 Apr 2025
Ended
30 Sept 2025
Type of study
Interventional, 2 groups
Treatments tested
  • RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE
  • HZ/su VACCINE
Record updated
6 November 2025

Who can take part

Age
50 years and older
Sex
Women and men
Healthy volunteers
Can take part

The registry criteria, word for word

Show all 10 criteriaShow less

Who can take part

  • Male and female participants 50 years of age and older who are healthy or with stable chronic medical conditions

Who cannot take part

  • Prior history of any subtype of Guillain Barré syndrome of any etiology
  • Previous vaccination with any licensed or investigational RSV vaccine at any time prior to enrollment, or planned receipt of a nonstudy RSV vaccine during study participation
  • Previous vaccination with any licensed recombinant adjuvant zoster vaccine (Shingrix) at any time prior to enrollment, or planned receipt of a nonstudy licensed VZV vaccine (Shingrix) during study participation
  • History of previous vaccination with live HZ vaccine (Zostavax) in the last 2 years from enrollment, or planned receipt through study participation
  • Previous vaccination with any investigational VZV vaccine at any time prior to enrollment, or planned receipt of a nonstudy investigational VZV vaccine during study participation
  • Individuals who receive chronic systemic treatment with immunosuppressive therapy, including cytotoxic agents, immunosuppressive monoclonal antibodies, systemic corticosteroids (defined as ≥20 mg/day of prednisone or equivalent for ≥14 days), eg, for cancer or an autoimmune disease, or radiotherapy, from 60 days before study intervention administration, or planned receipt throughout the study
  • Current clinically suspected or polymerase chain reaction (PCR)-confirmed ongoing episode of HZ and/or history of clinically suspected or PCR-confirmed HZ within the past 12 months
  • Serious chronic disorder, including metastatic malignancy, end-stage renal disease with or without dialysis, clinically unstable cardiac disease, or any other disorder that, in the investigator's opinion, excludes the participant from participating in the study
  • Immunocompromised individuals with known or suspected immunodeficiency, as determined by history and/or laboratory/physical examination, and medication list

Where in United States

Also in 1 other country, 1 site

  • Central Research AssociatesBirmingham, United States
  • Clinical Research ProfessionalsChesterfield, United States
  • Synexus Clinical Research US, IncChicago, United States
  • Centricity Research Columbus Georgia MultispecialtyColumbus, United States
  • Centricity Research Columbus Ohio MultispecialtyColumbus, United States
  • Alliance for Multispecialty Research, LLCDoral, United States
  • Proactive Clinical Research,LLCFort Lauderdale, United States
  • DM Clinical Research - BellaireHouston, United States
  • Medical Affiliated Research CenterHuntsville, United States
  • Kaiser PermanenteLos Angeles, United States
  • Clinical Neuroscience Solutions, Inc.Memphis, United States
  • SMS Clinical ResearchMesquite, United States
  • De La Cruz Research Center, LLCMiami, United States
  • AMR ClinicalMobile, United States
  • Delricht ResearchNew Orleans, United States
  • NYU Langone HealthNew York, United States
  • Optimal ResearchPeoria, United States
  • DM Clinical Research - PhiladelphiaPhiladelphia, United States
  • IMA Clinical Research San AntonioSan Antonio, United States
  • Jadestone Clinical ResearchSilver Spring, United States
  • Clinical Research AtlantaStockbridge, United States
  • DM Clinical Research, Sugar LandSugar Land, United States
  • Oakland Medical ResearchTroy, United States
  • Diablo Clinical Research, Inc.Walnut Creek, United States
  • IMA Clinical Research WarrenWarren Township, United States

About the trial

What the trial wants to find out

This purpose of this phase 3 multicenter, parallel-group, open-label study is to learn about the safety, tolerability, and immunogenicity of RSVpreF and HZ/su vaccine when given together in adults 50 years of age and older.

The 2 groups in the trial

  • Coadministration GroupOther group

    * Visit 1 (Day 1): RSVpreF + HZ/su dose 1 * Visit 3 (Month 2): HZ/su dose 2

    Treatment: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE and HZ/su VACCINE

  • Sequential Administration GroupOther group

    * Visit 1 (Day 1): HZ/su dose 1 * Visit 2 (Month 1): RSVpreF * Visit 3 (Month 2): HZ/su dose 2

    Treatment: RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE and HZ/su VACCINE

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A PHASE 3, MULTICENTER, PARALLEL-GROUP, OPEN-LABEL STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF RESPIRATORY SYNCYTIAL VIRUS PREFUSION F SUBUNIT VACCINE WHEN COADMINISTERED WITH HERPES ZOSTER SUBUNIT VACCINE IN ADULTS ≥50 YEARS OF AGE
Record updated
6 November 2025